Celltrion’s latest publication: https://onlinelibrary.wiley.com/journal/dth Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to biologics to improve care for U.S. patients. Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence, and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients.
External link for Celltrion USA
1 Evertrust Plaza
Jersey City, New Jersey 07302, US
Celltrion USA reposted this
Access to care shouldn’t depend on circumstances beyond a patient’s control. This World IBD Day, we are highlighting the importance of addressing disparities that impact how people experience and manage inflammatory bowel disease (IBD). Improving access means building a more responsive system – one that supports stability, reduces uncertainty, and helps patients navigate their care with confidence. #Celltrion #WorldIBDDay #IBD
Great moments from Digestive Disease Week 2026! It was inspiring to connect with experts, share insights, and engage in discussions on the latest advancements in gastroenterology. We appreciate everyone who stopped by our booth and contributed to these meaningful exchanges. #CelltrionUSA #DDW2026 US--26-00054 04/26
Celltrion USA was honored to support Bridging Autoimmunity 2026, a patient forum that brought together a wide range of voices across the autoimmune community. The event highlighted the importance of collaboration in addressing patient needs and advancing the understanding of autoimmune conditions. It also offered a valuable opportunity to connect with both healthcare professionals and patient communities, reinforcing the role of continued engagement and shared perspectives. We are proud to support initiatives like this that contribute to a more connected and patient-focused future in autoimmune care. #CelltrionUSA #autoimmunity2026 US--26-00055 04/26
We’re excited to share that Celltrion USA will be attending DDW 2026.Join us to explore how Celltrion USA is advancing science and expanding treatment possibilities in gastroenterology and immune-mediated diseases. Visit us at Booth #3951 to connect with our team and learn more about our latest developments. We look forward to seeing you in Chicago! #CelltrionUSA #DDW2026 US--26-00038 03/26
At the 2026 Digestive Disease Week (DDW), Celltrion USA will present seven abstracts in inflammatory bowel disease (IBD), including findings from the pivotal LIBERTY studies. The presentations feature long-term follow-up data and additional analyses, offering new insights to support clinical decision-making. These findings reflect our ongoing commitment to advancing IBD care in an evolving treatment landscape supporting effective disease management and helping improve patient outcomes. -View press release here: https://bit.ly/4vzHBNs #CelltrionUSA #DDW2026 US--26-00048 04/26
Innovation reaches patients through strong global science. At Celltrion USA, we connect the global R&D capabilities of Celltrion with the needs of patients and healthcare providers in the U.S. From biosimilars to next-generation therapeutics, Celltrion’s research platforms including advanced formulation technologies, cell line development, and microbiome research, support the development of innovative biologic medicines designed to expand treatment options. Together, we remain committed to advancing science and helping patients across the U.S. #CelltrionUSA US--26-00035 03/26
New scientific data regarding subcutaneous infliximab have been published [Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials]. The findings contribute to the evolving scientific understanding of treatment approaches in inflammatory bowel disease (IBD) and support informed clinical decision-making. Read the full publication here: https://bit.ly/4sR5ezw See full prescribing information, including a boxed warning: https://bit.ly/4uBAsvA #CelltrionUSA #InflammatoryBowelDiseases US-ZYM-26-00045 04/26
This World Health Day, we join the global call to stand #TogetherForScience. Science plays a vital role in advancing new treatments, strengthening healthcare systems, and improving the lives of patients around the world. At Celltrion USA, we are committed to science-driven innovation that helps expand access to high-quality biologic medicines and support better patient outcomes. #WorldHealthDay #TogetherForScience US--26-00034 03/26
April is National Cancer Control Month, a time to highlight the importance of prevention, early detection, and continued innovation in cancer care. At Celltrion USA, we recognize the critical role that science and collaboration play in advancing oncology treatment and improving patient outcomes. We remain committed to supporting innovation in biologic medicines and expanding treatment options that can help make a meaningful difference for cancer patients. #CelltrionUSA #CancerControlMonth US--26-00033 03/26
For many, spring brings blooming landscapes and warmer days. For others, it can bring increased exposure to allergens. Seasonal pollen and environmental triggers may worsen symptoms for people living with allergic asthma. Greater awareness of these triggers is essential to better understanding and continued scientific progress. Celltrion USA remains dedicated to patients living with allergic conditions in U.S. #CelltrionUSA #Allergy #Asthma US--26-00020 02/26